Stock Market & Financial Investment News

News Breaks August 3, 2012 11:33 EDT MNTA Momenta drops 5.5% after Bloomberg report of appeals court loss News For MNTA From The Last 14 Days Check below for free stories on MNTA the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 17, 2013 07:25 EDT MNTA Leerink to host a conference Subscribe for More Information June 6, 2013 10:01 EDT MNTA On The Fly: Analyst Upgrade Summary Subscribe for More Information 07:00 EDT MNTA Momenta Pharma upgraded to Buy from Neutral at UBS UBS upgraded Momenta (MNTA) based on increased confidence for generic Copaxone approval in time for a September 2015 launch when the patents expire and potentially earlier, in the event of a favorable appeals court decision vs. Teva (TEVA). Price target raised to $17 from $13. Sign up for a free trial to see the rest of the stories you've been missing.